SuperGen news from FierceBiotech

Shares of SuperGen took a dive this morning after the company revealed that Dacogen failed a late-stage trial for the bone marrow disease MDS. Researchers say the drug failed to improve the median Read more...

RHEI Pharmaceuticals, which is focused on introducing approved and late clinical-stage proprietary drugs from the U.S. into China, announced today that Timothy M. Kish has joined the company as president and CFO.

Charles P. Slacik has resigned as CFO of Watson Pharmaceuticals to become senior vice president and chief …

Read more...

A unit of Johnson & Johnson has inked an $80 million licensing pact for MGI Pharma's Dacogen, which was approved by the FDA last May for patients with myelodysplastic syndromes. MGI will split a $10 million up-front fee from Cilag with SuperGen, which developed the therapy and sold the rights to MGI in 2004. Milestone payments of up to $47 million will also be split and MGI will get $25 million in research money over the next three years. Cilag in turn gets development and marketing …

Read more...

J&J buys Pfizer's OTC division for $16.6B

Read more...

Mayne Pharma is buying the North American rights to the leukemia drug Nipent and a medical surface cleaner from SuperGen for $15 million up front and up to $19 million in milestone payments. Mayne also says it is in talks to buy the cancer therapy mitmycin for the U.S. from SuperGen. "The addition of Nipent fits our strategy perfectly, building on our core oncology capability, particularly in the important US market," Mayne chief executive Dr Thierry Soursac said.

- read the …

Read more...

> MGI Pharma's move to begin marketing Dacogen as a blood cell disease therapy triggered a $20 million milestone payment to SuperGen. Report

> Cubist Pharmaceuticals scored a big win with the FDA's approval late yesterday for expanding the use of Cubicin to include bloodstream infections. Cubist has made expanded approval a key strategy and expects to net millions of …

Read more...

Shares of MGI Pharma took a positive bounce on the news that the FDA had approved its blood cell therapy Dacogen. Dacogen is designed to treat myelodysplastic syndromes (MDS), a disease category that is characterized by poorly functioning blood cells. Phase III data suggest that about one in five patients respond to the drug, which will be launched in the second quarter. SuperGen developed Dacogen and now stands to benefit from its sale.

"This approval is a significant milestone …

Read more...

SuperGen says a Phase II trial of Orathecin plus gemcitabine as a first-line combination therapy for advanced pancreatic cancer patients who have not undergone chemotherapy failed to demonstrate sufficient gains in median survival rates to warrant its advance into a Phase III study. One-year survival statistics were "encouraging," says the company, and Orathecin demonstrated the same safety profile as seen in Phase I.

"We are working with our clinical advisors, investigators and …

Read more...

Angiotech follows a combinational route.

Read more...

SuperGen has inked a deal to acquire Salt Lake City-based Montigen for $18 million in cash and stock. Montigen shareholders will also be eligible to earn up to $22 million more based on established regulatory milestones. Montigen has late-stage compounds in its pre-clinical portfolio. These include inhibitors of aurora-A kinase and products which target the tyrosinekinase receptor family. The compounds have shown pre-clinical activity in solid tumors of several cancer types.

- read this article from the UPI